ADVERTISEMENT
Psychedelics Briefs: Numinus Wellness, MAPS Public Benefit Corporation
Numinus Announces Corporate Ketamine-Assisted Therapy Pilot, Visual Rebrand
Numinus Wellness announced that it is launching a pilot program in Utah to help businesses improve employee mental health by offering ketamine-assisted psychotherapy as a health benefit for eligible employees. Under the program, employers will cover the cost of ketamine infusions while leveraging existing healthcare insurance plans to support the program’s therapy component.
The program will follow the model established in a pilot by Numinus’s Utah clinics, which operate under the Cedar Psychiatry brand and Utah-based HempLucid since 2019.
In a separate announcement, Numinus also said this week that the company is launching a new visual brand identity that will be applied to all of its assets, including its clinics, research sites, and digital properties. The refreshed brand, which was developed in collaboration with the creative agency GrandArmy, will be rolled out in phases through the end of 2022.
Current Numinus-branded assets and website are being immediately rebranded, while subsidiaries Mindspace, the Neurology Centre of Toronto, Cedar Psychiatry, Cedar Clinical Research, and Foundations of Change will follow later in the year.
MAPS Public Benefit Corp. Selects Contract Research Organization to Develop New Drug Application
MAPS Public Benefit Corporation announced this week that it has selected MMS Holdings as its contract research organization for the development of a new drug application for MDMA-assisted therapy for post-traumatic stress disorder (PTSD). The announcement comes after the organization finished enrollment for its confirmatory Phase 3 trial, MAPP2, last month.
MAPP1, the first of 2 Phase 3 trials, showed that 88% of participants experienced a mean 44.7% reduction in PTSD symptoms 2 months after their last experimental session.
For the new drug application, MMS will provide regulatory strategy, biostatistics, statistical programming, medical writing, medical review, publishing, and submission project management support. MMS provides support for an average of 8 to 12 new drug applications for year.
References
